Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...

Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...

Varonis Systems (VRNS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results ...

Final data from ORIGIN and VISIONARY trials pave way for full FDA approvals ...

Significant proteinuria reductions reported, but still awaiting eGFR data ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Boston Scientific (BSX) with bullish sentiments. According to TipRanks.com, CFA is a ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

The new Kidney Care National Plan from the US Department of Health and Human Services focuses on preventing kidney failure, ...